Insider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Major Shareholder Sells $247,200.00 in Stock

The Oncology Institute, Inc. (NASDAQ:TOIGet Rating) major shareholder Havencrest Healthcare Partners sold 80,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $3.09, for a total value of $247,200.00. Following the sale, the insider now directly owns 13,789,475 shares in the company, valued at approximately $42,609,477.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Havencrest Healthcare Partners also recently made the following trade(s):

  • On Monday, November 7th, Havencrest Healthcare Partners sold 19,167 shares of Oncology Institute stock. The stock was sold at an average price of $3.28, for a total transaction of $62,867.76.
  • On Friday, November 4th, Havencrest Healthcare Partners sold 50,200 shares of Oncology Institute stock. The stock was sold at an average price of $3.39, for a total transaction of $170,178.00.
  • On Wednesday, November 2nd, Havencrest Healthcare Partners sold 58,500 shares of Oncology Institute stock. The stock was sold at an average price of $3.94, for a total transaction of $230,490.00.
  • On Monday, October 31st, Havencrest Healthcare Partners sold 41,855 shares of Oncology Institute stock. The stock was sold at an average price of $4.69, for a total transaction of $196,299.95.
  • On Friday, October 28th, Havencrest Healthcare Partners sold 52,091 shares of Oncology Institute stock. The stock was sold at an average price of $4.84, for a total transaction of $252,120.44.
  • On Wednesday, October 26th, Havencrest Healthcare Partners sold 52,500 shares of Oncology Institute stock. The stock was sold at an average price of $5.16, for a total transaction of $270,900.00.
  • On Monday, October 24th, Havencrest Healthcare Partners sold 29,400 shares of Oncology Institute stock. The stock was sold at an average price of $4.98, for a total transaction of $146,412.00.
  • On Thursday, October 20th, Havencrest Healthcare Partners sold 12,000 shares of Oncology Institute stock. The stock was sold at an average price of $4.83, for a total transaction of $57,960.00.
  • On Monday, October 17th, Havencrest Healthcare Partners sold 8,249 shares of Oncology Institute stock. The stock was sold at an average price of $4.60, for a total transaction of $37,945.40.
  • On Friday, October 14th, Havencrest Healthcare Partners sold 9,800 shares of Oncology Institute stock. The stock was sold at an average price of $4.54, for a total transaction of $44,492.00.

Oncology Institute Stock Down 26.2 %

Shares of NASDAQ:TOI opened at $2.17 on Friday. The firm has a fifty day moving average of $4.61 and a two-hundred day moving average of $6.01. The firm has a market capitalization of $159.02 million, a P/E ratio of -12.76 and a beta of 1.71. The Oncology Institute, Inc. has a 12-month low of $2.14 and a 12-month high of $12.66.

Institutional Investors Weigh In On Oncology Institute

A number of institutional investors have recently modified their holdings of TOI. Qube Research & Technologies Ltd boosted its stake in shares of Oncology Institute by 102.5% during the 1st quarter. Qube Research & Technologies Ltd now owns 37,850 shares of the company’s stock valued at $270,000 after buying an additional 19,162 shares during the period. Triatomic Management LP lifted its stake in shares of Oncology Institute by 7.0% in the 1st quarter. Triatomic Management LP now owns 428,100 shares of the company’s stock valued at $3,052,000 after purchasing an additional 28,100 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Oncology Institute by 89.5% in the 1st quarter. Vanguard Group Inc. now owns 838,321 shares of the company’s stock valued at $5,977,000 after purchasing an additional 395,977 shares during the last quarter. Northern Trust Corp acquired a new stake in shares of Oncology Institute in the 1st quarter valued at $129,000. Finally, State Street Corp acquired a new stake in shares of Oncology Institute in the 1st quarter valued at $222,000. Institutional investors and hedge funds own 69.97% of the company’s stock.

Wall Street Analysts Forecast Growth

TOI has been the topic of several research analyst reports. Jefferies Financial Group initiated coverage on shares of Oncology Institute in a research report on Monday, August 15th. They set a “buy” rating and a $10.00 price objective on the stock. Guggenheim lowered their price objective on shares of Oncology Institute from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday.

Oncology Institute Company Profile

(Get Rating)

The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.

Featured Articles

Insider Buying and Selling by Quarter for Oncology Institute (NASDAQ:TOI)

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.